We’ve recently updated our valuation analysis.

NIOX Group Valuation

Is 82C undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 82C?

Other financial metrics that can be useful for relative valuation.

82C key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue5.4x
Enterprise Value/EBITDA29.1x
PEG Ratio-1.8x

Price to Earnings Ratio vs Peers

How does 82C's PE Ratio compare to its peers?

The above table shows the PE ratio for 82C vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPEEstimated GrowthMarket Cap
Peer Average20.7x
FYB Formycon
13.7x40.1%€1.1b
PSG PharmaSGP Holding
31.2x12.8%€343.2m
B8F Biofrontera
6.7x41.7%€75.0m
APPH Apontis Pharma
31.3x46.5%€84.1m
82C NIOX Group
13.3x-7.5%€186.9m


Price to Earnings Ratio vs Industry

How does 82C's PE Ratio compare vs other companies in the European Biotechs Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a48.1%
n/an/an/a
No. of CompaniesPE048121620

Fetching data

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a48.1%
n/an/an/a
No more companies


Price to Earnings Ratio vs Fair Ratio

What is 82C's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

82C PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio13.3x
Fair PE Ratio8.6x

Price-To-Earnings vs Fair Ratio: 82C is expensive based on its Price-To-Earnings Ratio (13.3x) compared to the estimated Fair Price-To-Earnings Ratio (8.6x).


Share Price vs Fair Value

What is the Fair Price of 82C when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 82C forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€0.48
€0.62
+28.7%
3.8%€0.65€0.59n/a3
Apr ’24€0.49
€0.62
+26.0%
3.8%€0.65€0.59n/a3
Mar ’24€0.51
€0.56
+11.5%
12.2%€0.63€0.47n/a3
Feb ’24€0.40
€0.56
+40.8%
12.2%€0.63€0.47n/a3
Jan ’24€0.38
€0.55
+46.7%
12.0%€0.64€0.47n/a3
Dec ’23€0.38
€0.55
+45.9%
12.0%€0.64€0.47n/a3
Nov ’23€0.40
€0.55
+37.2%
12.0%€0.64€0.47n/a3
Oct ’23€0.38
€0.51
+33.2%
6.8%€0.54€0.47n/a2
Sep ’23€0.37
€0.53
+43.6%
6.8%€0.56€0.49n/a2
Aug ’23€0.39
€0.52
+33.8%
6.8%€0.56€0.49n/a2
Jul ’23€0.36
€0.55
+51.1%
12.1%€0.61€0.48n/a2
Jun ’23€0.39
€0.55
+39.5%
12.1%€0.61€0.48n/a2
May ’23€0.40
€0.55
+38.1%
12.1%€0.61€0.48n/a2
Apr ’23€0.40
€0.55
+36.8%
12.1%€0.61€0.48€0.492
Mar ’23€0.43
€0.48
+11.8%
0%€0.48€0.48€0.511
Feb ’23€0.50
€0.48
-4.3%
0%€0.48€0.48€0.401
Jan ’23€0.46
€0.48
+2.8%
0%€0.48€0.48€0.381
Dec ’22€0.43
€0.48
+11.9%
0%€0.48€0.48€0.381
Apr ’22€0.32
€0.25
-22.3%
0%€0.25€0.25€0.401


Discover undervalued companies